Synta Pharmaceuticals Announces Presentations at the 2013 Annual Meeting of the American Association for Cancer Research
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that poster presentations related to studies with ganetespib, a selective Hsp90 inhibitor in clinical development by the company, will be presented at the 2013 Annual Meeting of the American Association of Cancer Research in Washington, D.C. Presentations include:
Inhibition of mTOR enhances the activity of HSP90 inhibitors in part through cessation of heat shock protein synthesis
Inhibition of mTOR enhances the activity of HSP90 inhibitors in part through cessation of heat shock protein synthesis